|
1
|
Siegel RL, Miller KD, Fuchs HE and Jemal
A: Cancer statistics, 2022. CA Cancer J Clin. 72:7–33. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Rini BI, Battle D, Figlin RA, George DJ,
Hammers H, Hutson T, Jonasch E, Joseph RW, McDermott DF, Motzer RJ,
et al: The society for immunotherapy of cancer consensus statement
on immunotherapy for the treatment of advanced renal cell carcinoma
(RCC). J Immunother Cancer. 7:3542019. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Pal SK, Ghate SR, Li N, Swallow E, Peeples
M, Zichlin ML, Perez JR, Agarwal N and Vogelzang NJ: Real-world
survival outcomes and prognostic factors among patients receiving
first targeted therapy for advanced renal cell carcinoma: A
SEER-medicare database analysis. Clin Genitourin Cancer.
15:e573–e582. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Motzer RJ, Tannir NM, McDermott DF, Arén
Frontera O, Melichar B, Choueiri TK, Plimack ER, Barthélémy P,
Porta C, George S, et al: Nivolumab plus ipilimumab versus
sunitinib in advanced renal-cell carcinoma. N Engl J Med.
378:1277–1290. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Motzer RJ, Penkov K, Haanen J, Rini B,
Albiges L, Campbell MT, Venugopal B, Kollmannsberger C, Negrier S,
Uemura M, et al: Avelumab plus axitinib versus sunitinib for
advanced renal-cell carcinoma. N Engl J Med. 380:1103–1115. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Rini BI, Plimack ER, Stus V, Gafanov R,
Hawkins R, Nosov D, Pouliot F, Alekseev B, Soulières D, Melichar B,
et al: Pembrolizumab plus axitinib versus sunitinib for advanced
renal-cell carcinoma. N Engl J Med. 380:1116–1127. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Choueiri TK, Powles T, Burotto M, Escudier
B, Bourlon MT, Zurawski B, Oyervides Juárez VM, Hsieh JJ, Basso U,
Shah AY, et al: Nivolumab plus cabozantinib versus sunitinib for
advanced renal-cell carcinoma. N Engl J Med. 384:829–841. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Motzer R, Alekseev B, Rha SY, Porta C, Eto
M, Powles T, Grünwald V, Hutson TE, Kopyltsov E, Méndez-Vidal MJ,
et al: Lenvatinib plus pembrolizumab or everolimus for advanced
renal cell carcinoma. N Engl J Med. 384:1289–1300. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Choueiri TK, Xie W, Kollmannsberger C,
North S, Knox JJ, Lampard JG, McDermott DF, Rini BI and Heng DY:
The impact of cytoreductive nephrectomy on survival of patients
with metastatic renal cell carcinoma receiving vascular endothelial
growth factor targeted therapy. J Urol. 185:60–66. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Bhindi B, Abel EJ, Albiges L, Bensalah K,
Boorjian SA, Daneshmand S, Karam JA, Mason RJ, Powles T and Bex A:
Systematic review of the role of cytoreductive nephrectomy in the
targeted therapy era and beyond: An individualized approach to
metastatic renal cell carcinoma. Eur Urol. 75:111–128. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Singla N, Hutchinson RC, Ghandour RA,
Freifeld Y, Fang D, Sagalowsky AI, Lotan Y, Bagrodia A, Margulis V,
Hammers HJ and Woldu SL: Improved survival after cytoreductive
nephrectomy for metastatic renal cell carcinoma in the contemporary
immunotherapy era: An analysis of the national cancer database.
Urol Oncol. 38:604.e9–604.e17. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Hall ME, Bhindi B, Luckenbaugh AN, Laviana
AA, Moses KA, Satkunasivam R, Rini B, Klaassen Z and Wallis CJD:
Association between cytoreductive nephrectomy and survival among
patients with metastatic renal cell carcinoma receiving modern
therapies: A systematic review and meta-analysis examining effect
modification according to systemic therapy approach. Cancer Causes
Control. 32:675–680. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Bex A, Mulders P, Jewett M, Wagstaff J,
van Thienen JV, Blank CU, van Velthoven R, Del Pilar Laguna M, Wood
L, van Melick HHE, et al: Comparison of immediate vs deferred
cytoreductive nephrectomy in patients with synchronous metastatic
renal cell carcinoma receiving sunitinib: The SURTIME randomized
clinical trial. JAMA Oncol. 5:164–170. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Méjean A, Ravaud A, Thezenas S, Colas S,
Beauval JB, Bensalah K, Geoffrois L, Thiery-Vuillemin A, Cormier L,
Lang H, et al: Sunitinib alone or after nephrectomy in metastatic
renal-cell carcinoma. N Engl J Med. 379:417–427. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Heng DYC, Xie W, Regan MM, Warren MA,
Golshayan AR, Sahi C, Eigl BJ, Ruether JD, Cheng T, North S, et al:
Prognostic factors for overall survival in patients with metastatic
renal cell carcinoma treated with vascular endothelial growth
factor-targeted agents: Results from a large, multicenter study. J
Clin Oncol. 27:5794–5799. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Yates JW, Chalmer B and McKegney FP:
Evaluation of patients with advanced cancer using the Karnofsky
performance status. Cancer. 45:2220–2224. 1980. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Eisenhauer EA, Therasse P, Bogaerts J,
Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S,
Mooney M, et al: New response evaluation criteria in solid tumours:
Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Stühler V, Herrmann L, Rausch S, Stenzl A
and Bedke J: Real world data on IO-based therapy for metastatic
renal cell carcinoma. J Cancer Res Clin Oncol. 149:3249–3258. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Iinuma K, Yamada T, Kameyama K, Taniguchi
T, Kawada K, Ishida T, Nagai S, Enomoto T, Ueda S, Takagi K, et al:
The efficacy and safety of immune checkpoint inhibitor and tyrosine
kinase inhibitor combination therapy for advanced or metastatic
renal cell carcinoma: A multicenter retrospective real-world cohort
study. Cancers (Basel). 15:9472023. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Bosma NA, Warkentin MT, Gan CL, Karim S,
Heng DYC, Brenner DR and Lee-Ying RM: Efficacy and safety of
first-line systemic therapy for metastatic renal cell carcinoma: A
systematic review and network meta-analysis. Eur Urol Open Sci.
37:14–26. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ernst MS, Navani V, Wells JC, Donskov F,
Basappa N, Labaki C, Pal SK, Meza L, Wood LA, Ernst DS, et al:
Outcomes for international metastatic renal cell carcinoma database
consortium prognostic groups in contemporary first-line combination
therapies for metastatic renal cell carcinoma. Eur Urol.
84:109–116. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Hara T, Furukawa J, Shiraishi Y, Okamura
Y, Bando Y, Terakawa T, Harada K, Nakano Y and Fujisawa M: Impact
of cytoreductive nephrectomy prior to combination therapy of
ipilimumab plus nivolumab in metastatic renal cell carcinoma. Int J
Urol. May 2–2023.(Epub ahead of print). View Article : Google Scholar
|
|
23
|
Escudier B, Motzer RJ, Tannir NM, Porta C,
Tomita Y, Maurer MA, McHenry MB and Rini BI: Efficacy of nivolumab
plus ipilimumab according to number of IMDC risk factors in
CheckMate 214. Eur Urol. 77:449–453. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Dudani S, Graham J, Wells JC, Bakouny Z,
Pal SK, Dizman N, Donskov F, Porta C, de Velasco G, Hansen A, et
al: First-line immuno-oncology combination therapies in metastatic
renal-cell carcinoma: Results from the international metastatic
renal-cell carcinoma database consortium. Eur Urol. 76:861–867.
2019. View Article : Google Scholar : PubMed/NCBI
|
